Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Must be able to adhere to dose and visit schedules~* ≥ 40 kg~* Hepatitis B surface antigen (HBsAg) positive for at least 6 months~* Anti-HBs negative~* Female participants of childbearing potential must agree to use an acceptable~method of contraception from at least 2 weeks prior to Day 1 and continue until at least 1 month after last dose of study drug~Inclusion Criteria for HBeAg(+) participants:~* HBeAg(+)~* Anti-HBe(-)~Inclusion Criteria for HBeAg(-) participants:~* HBeAg(-)~* Anti-HBe(+)~Exclusion Criteria:~* Co-infection with the human immunodeficiency virus (HIV) or hepatitis C or hepatitis D virus~* Prior treatment with interferon for hepatitis B~* Use of nucleoside/nucleotide analogues within 6 months of the screening visit or at any time during the study~* Use of any investigational drug within 30 days of the screening visit~* Prior treatment with herbal remedies with known hepatotoxicity. All herbal remedies used for hepatitis B treatment must be discontinued before Day 1~* Evidence of decompensated liver disease including, but not limited to, a history or presence of clinical ascites, bleeding varices, or hepatic encephalopathy~* Diabetic and/or hypertensive with clinically significant ocular examination findings~* History of stroke or transient ischemic attack~* Immunologically mediated disease (e.g., inflammatory bowel disease \[Crohn's disease, ulcerative colitis\], celiac disease, rheumatoid arthritis, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, autoimmune hemolytic anemia, scleroderma, sarcoidosis, severe psoriasis requiring oral or injected treatment, or symptomatic thyroid disorder)~* Chronic pulmonary disease (e.g., chronic obstructive pulmonary disease, interstitial lung disease, pulmonary fibrosis, sarcoidosis)~* Current or history of any clinically significant cardiac abnormalities/dysfunction~* Any medical condition requiring, or likely to require, chronic systemic administration of corticosteroids during the course of the trial~* Myelodysplastic syndromes~* Organ transplants (including hematopoietic stem cell transplants) other than cornea and hair~* Pregnant or nursing, or intending to become pregnant during the trial period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HBeAg(+) PEG-Intron (Type: EXPERIMENTAL): HBeAg-positive participants receive 1.5 mcg/kg/wk PEG-Intron subcutaneously (SC) once weekly for 48 weeks.
- HBeAg(+) PEGASYS (Type: ACTIVE_COMPARATOR): HBeAg-positive participants receive 180 mcg/kg/wk PEGASYS SC once weekly for 48 weeks.
- HBeAg(-) PEG-Intron (Type: EXPERIMENTAL): HBeAg-negative participants receive 1.5 mcg/kg/wk PEG-Intron SC once weekly for 48 weeks.
- HBeAG(-) PEGASYS (Type: ACTIVE_COMPARATOR): HBeAg-negative participants receive 180 mcg/kg/wk PEGASYS SC once weekly for 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).